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Aminoglycoside (AG) antibiotics are associated with several
side effects, including a reversible nephrotoxicity and a
permanent ototoxicity. Oxidative stress is thought to
contribute to the pathophysiology of both conditions. We
studied the possible protective effect of the antioxidant
N-acetylcysteine (NAC) in gentamicin-induced hearing loss in
hemodialysis patients. This study includes 53 hemodialysis
patients scheduled to receive gentamicin for dialysis
catheter-related bacteremia that were randomized to receive
the antibiotic with or without NAC. Hearing function was
assessed by the standard technique of pure-tone audiograms
over a range of frequencies. Audiometric evaluations were
performed at baseline, 1 week and at 6 weeks after the
completion of gentamicin therapy. A total of 40 patients
completed the study protocol with a mean duration of
therapy of almost 15 days. At both 1 and 6 weeks after the
completion of antibiotic therapy, there were significantly
more patients exhibiting ototoxicity in the control group
compared with the group receiving NAC. Additionally,
significantly more patients in the control group had bilateral
ototoxicity. The greatest otoprotective effect of NAC was
noticed in the high audiometric tone frequencies. Taken
together, our study suggests that NAC treatment may
ameliorate gentamicin-induced ototoxicity in hemodialysis
patients.
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Aminoglycoside (AG) antibiotics are important drugs in the
treatment of several life-threatening infections, especially
those caused by Gram-negative bacteria.1 Sixty years after
their introduction, AGs remain the drugs of choice in many
circumstances, including bacterial endocarditis, peritonitis,
and line sepsis.1 Unfortunately, AGs are associated with
several side effects, including nephrotoxicity and ototoxicity.2
The renal toxicity is generally reversible, whereas the damage
to the cochlear and the vestibular systems may lead to
permanent loss of hearing and balance, respectively.3
The prevalence of AG-induced ototoxicity is 3–25%.4
However, when high-frequency audiograms were performed,
the prevalence was as high as 62%.5 Hemodialysis patients are
a special vulnerable group, frequently requiring AG therapy
due to vascular access infection or line sepsis. Because 99% of
AG is excreted by the kidneys, patients with end-stage renal
disease (ESRD) have increased risk of AG ototoxicity.6 Several
measures have been proposed to prevent AG ototoxicity,
including monitoring of plasma blood levels with subsequent
dose adjustment, once-daily dosing schedule, or shortening
duration of therapy if clinically appropriate.1,7,8 Unfortu-
nately, none of these measures have proved to be effective.7,8
The most promising hypothesis, explaining AG ototoxi-
city, is based on reactive oxygen species damage to the inner
ear.9 In animal studies, co-administration of antioxidant
therapy ameliorated AG ototoxicity.10 Recently, Sha et al.11
have demonstrated that aspirin may have a protective effect
against AG-induced ototoxicity. N-acetylcysteine (NAC), a
thiol-containing antioxidant, has been used successfully to
ameliorate the toxic effects of a variety of substances on liver,
heart, kidney, and lung.12–15 NAC may prevent hearing loss
associated with bacterial meningitis16 and auditory hair cell
damage from cisplatin.17 NAC can also ameliorate gentami-
cin-induced nephrotoxicity.18 The aim of this study was to
evaluate the protective effect of NAC against gentamicin-
induced ototoxicity in ESRD patients treated with hemodia-
lysis.
RESULTS
Fifty-three patients were enrolled in the study and underwent
baseline otologic examination (Figure 1). Twenty-six patients
were in the NAC-treated group and 27 in the control group.
Thirteen patients did not complete the study protocol: one
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patient in each group died from sepsis; one patient from
control group died from acute coronary event; six patients
had an air-bone difference 410 dB; three were unable to
cooperate with serial audiograms; and one withdrew his
consent. Forty patients completed the study protocol, 20
patients in each group. There was no statistically significant
difference between the groups in any of the baseline patients’
clinical characteristics, as well as in the baseline hearing
threshold levels on audiometric examination (Table 1). All
uncuffed catheters had been removed immediately in case of
suspected line-related bacteremia.
The characteristics of the present gentamicin course were
similar in both groups (Table 1). Mean duration of therapy
with gentamicin was 14.7573.82 days in the NAC-treated
group and 14.2875.76 days in the control group (P¼ 0.76).
The cumulative gentamicin dose was 675.57242.02 mg in
the NAC-treated group and 694.57249.02 mg in the control
group (P¼ 0.81). The cumulative dose corrected for patients’
weight was 9.7873.55 mg/kg in the NAC-treated group and
9.674.11 mg/kg in the control group (P¼ 0.88). Mean
predialysis blood level of gentamicin was 3.0270.62 mcg/ml
in the NAC group and 2.8770.64 mcg/ml in the control
group (P¼ 0.46). Clinical effect of antibiotic therapy did not
differ between the groups. There were no side effects that
could be related to NAC therapy during the follow-up period.
The results of the otologic evaluation are summarized in
Table 2. During the study period, ototoxicity developed in 12
patients (60%) from the control group and in five patients
(25%) from the NAC group; 41.6% risk reduction
(P¼ 0.025). At the early follow-up examination (773 days
after completing gentamicin therapy), 11 patients (55%) in
the control group and four patients (20%) in the NAC group
fulfilled the ototoxicity criteria (P¼ 0.022). At the late
follow-up examination (4273 days after completing genta-
micin therapy), 11 patients (55%) in the control group and
two patients (10%) in the NAC group still fulfilled the
ototoxicity criteria (P¼ 0.002). One patient (5%) from the
NAC group and six patients (30%) from the control group
had bilateral ototoxicity (P¼ 0.037).
The maximal change in hearing threshold in the control
group, as well as the most significant benefit in the NAC
group, were noticed in the high audiometric frequencies,
PTA-3 (Table 2, Figure 2). The mean change in PTA-3 at early
follow-up was 5.8375.14 dB in the control group and
2.0073.8 dB in the NAC-treated group (P¼ 0.011). The
53 patients
randomized
N-acetylcysteine group
26 Patients 
Control group
27 Patients
20 patients
completed the study
20 patients
completed the study 
One died (sepsis)
Three had air-bone 
discrepancy
Two were unable to
cooperate with
serial audiometery
Two died (sepsis, MI)
Three had air-bone 
discrepancy
One were unable to cooperate
with serial audiometery
One withdraw consent  
Figure 1 | Study design.
Table 1 | Patients characteristics
N-acetylcysteine
(n=20)
Control
(n=20) P-value
Age (years) 65.8712.5 59.8711.5 0.12
Gender, female (%) 8 (40%) 7 (35%) 0.50
Weight (kg) (post dialysis) 72.4719.1 74.5718.0 0.71
Months on dialysis 28.6732.6 27.6739.8 0.93
Hemodialysis adequacy (Kt/V) 1.2670.28 1.1570.23 0.19
Cuffed catheter, patients (%) 12 (60%) 14 (70%) 0.507
Systolic BP (mmHg) 145.35725.0 133.25720.8 0.11
Diastolic BP (mmHg) 73.35710.77 71.3579.2 0.53
Fever4381C, patients (%) 15 (75%) 13 (65%) 0.46
Respiratory rate per minute 22.3073.45 20.8073.636 0.189
Hb (g/l) 105.3716.6 107.6713.3 0.68
WBC ( 10ł/ml) 15.472.8 14.972.6 0.64
Albumin (g/l) 35.774.6 34.073.78 0.19
Renal disease, patients
Diabetic nephropathy 8 (40%) 9 (45%) 0.50
Hypertension 7 (35%) 3 (15%) 0.137
Chronic glomerulopathy 1 (5%) 2 (10%) 0.50
Polycystic kidney 2 (10%) 2 (10%) 1.0
Obstructive uropathy 2 (10%) 1 (5%) 0.50
Other/unknown 0 (0%) 3 (15%) 0.115
Diabetes mellitus, patients 9 (45%) 11 (55%) 0.376
Present smoker, patients 4 (20%) 6 (30%) 0.36
Previous AG therapy, patients 8 (40%) 6 (30%) 0.37
Present gentamicin course
Duration (days) 14.7573.82 14.2875.76 0.76
Cumulative dose (total mg) 675.57242.02 694.57249.02 0.81
Cumulative dose (mg/kg) 9.7873.55 9.674.11 0.88
Blood predialysis level (mg/ml) 3.0270.62 2.8770.64 0.46
Bacteriological data, patients
Pseudomonas sp 4 (20%) 6 (30%) 0.36
Enterobacteriaceae 6 (30%) 7 (35%) 0.45
Other Gram-negative 4 (20%) 2 (10%) 0.331
Enterococcus sp 4 (20%) 2 (10%) 0.331
Culture-negative 2 (10%) 3 (15%) 0.50
Baseline hearing level, dB
PTA-1 28.5711.3 28.3710.23 0.92
PTA-2 45.16719.59 39.9715.08 0.35
PTA-3 66.58720.49 59.33716.71 0.23
AG, aminoglycoside; BP, blood pressure; PTA, pure-tone average hearing threshold;
PTA-1, PTA at frequencies 250, 500, and 1 000 Hz; PTA-2, PTA at frequencies 2 000,
3 000, and 4 000 Hz; PTA-3, PTA at frequencies 6 000, 8 000, and 12 000 Hz.
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mean change in PTA-3 at late follow-up was 7.0078.15 dB in
the control group and 2.0875.18 dB in the NAC-treated
group (P¼ 0.029).
Four patients (20%) in the control group and five patients
(25%) in the NAC-treated group had tinnitus during the
follow-up period (P¼ 0.705). Eight patients (40%) from the
control group and four patients (20%) in the NAC-treated
group had any vertigo sensation during the follow-up period
(P¼ 0.168).
DISCUSSION
Hearing loss is a major complication of AG therapy. This
study evaluated the protective effect of NAC against AG-
induced hearing loss in the high-risk group of hemodialysis
patients. In the NAC-treated group, there was a significant
reduction of ototoxicity compared to the control group
(41.6% reduction, P¼ 0.025). NAC exerted its protective
effect mainly in the high audiometric frequencies
(6 000–12 000 Hz). No adverse events related to NAC therapy
were recorded during the follow-up period.
Sixty years after their discovery, AGs remain an important
tool in the armamentarium of anti-infectious drugs. AGs are
part of the standard therapy used for bacterial endocarditis,
sepsis, and peritonitis.1 Moreover, the use of AG is increasing
in at least three groups of patients: patients suffering from
bronchiectasis, including those with cystic fibrosis;19,20
patients suffering from multidrug-resistant TB;21 and line
sepsis or peritonitis in the constantly growing group of
dialysis patients.22,23 AGs have several advantages over other
antibiotics with the same antibacterial spectrum, as newer
b-lactams and fluoroquinilones: the prevalence of bacterial
resistance against AG remained relatively low; allergic
reactions are rare, and the cost is low.1 In this study, AG
therapy was given as part of the routinely used antibiotic
therapy for central line-related bacteremia in hemodialysis
patients.
Several measures such as drug levels monitoring, once-
daily administration, and audiometric tests have been
traditionally used to prevent AG ototoxicity.7,8 Unfortunately,
they are not free of some caveats. Careful monitoring of
serum concentration is important; however, ototoxicity can
occur within the recommended therapeutic range.7 Once-
daily administration of AG has not proved to diminish
ototoxicity and is not suitable for patients with subacute
bacterial endocarditis.8 The benefit of widely recommended
audiometric testing is even less certain. Indeed, early
detection of ototoxicity may lead to discontinuation of AG,
but ototoxicity may develop or progress well after their
cessation.7 AG can be retained in the cochlea for as long as 11
months after the drug administration and is known to cause
delayed hearing loss.24 Additionally, the clinical condition of
many seriously ill patients precludes performance of full
audiologic examination. Enormous cost and effort required
for such testing makes it unpractical for routine clinical use.
The beneficial effect of NAC on cochlear function in the
special context of AG-induced ototoxicity observed in this
Table 2 | Effect of N-acetylcysteine on otologic outcomes
N-acetylcysteine
(n=20)
Control
(n=20) P-value
Audiologic toxicity, patients (%)
Total 5 (25%) 12 (60%) 0.027
Earlya 4 (20%) 11 (55%) 0.024
Lateb 2 (10%) 11 (55%) 0.003
Bilateral 1 (5%) 6 (30%) 0.01
Tinnitus,
patients (%)
5 (25%) 4 (20%) 0.50
Vertigo,
patients (%)
4 (20%) 8 (40%) 0.15
Mean hearing loss at early follow-up (dB)
PTA-1 1.8374.11 1.3373.73 0.015
PTA-2 0.5874.46 2.0874.64 0.072
PTA-3 2.0073.80 5.8375.14 0.011
Mean hearing loss at late follow-u, (dB)
PTA-1 0.7574.27 2.2576.56 0.095
PTA-2 0.1674.32 4.3378.36 0.055
PTA-3 2.0875.18 7.0078.15 0.029
PTA, pure-tone average hearing threshold; PTA-1, PTA at frequencies 250, 500, and
1 000 Hz; PTA-2=PTA at frequencies 2 000, 3 000, and 4 000 Hz; PTA-3=PTA at
frequencies 6 000, 8 000, and 12 000 Hz.
a773 days after completing gentamicin therapy.
b4273 days after completing gentamicin therapy.
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Figure 2 | Mean change from baseline in air conduction threshold
(mean hearing loss). (a) Mean hearing loss at early follow-up (773
days after completing gentamicin therapy). (b) Mean hearing loss at
late follow-up (4273 days after completing gentamicin therapy).
*Po0.05. PTA¼pure-tone average hearing threshold. PTA-1¼ PTA at
frequencies 250, 500, and 1 000 Hz. PTA-2¼ PTA at frequencies 2 000,
3 000, and 4 000 Hz. PTA-3¼ PTA at frequencies 6 000, 8 000, and
12 000 Hz.
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study might be explained by its antioxidant properties. NAC,
a thiol-containing antioxidant, has been used originally as a
mucolitic drug in a variety of pulmonary diseases. Further, it
became the drug of choice for acute acetaminophen
poisoning.12 Recently, it has been used successfully in several
models of ischemic and toxic injuries to the heart, kidney,
liver, and lung.13–15,18 In each of these syndromes, it is
thought that the activity of NAC is mediated, at least in part,
by its antioxidant properties.
In a study performed by Farr et al.25, using animal
model, it was found that NAC crosses the blood–brain
barrier and accordingly may exhibit its protective effect
directly within the central nervous system. In healthy
volunteers, the absorption of orally administrated NAC is
rapid (tmax¼ 1.470.7 h), and after administration of
800 mg/m2/day the mean Cmax was 8.974.9 mg/ml.
26
Unfortunately, currently, there are insufficient data
regarding the pharmacokinetics of NAC in patients with
ESRD, and it may be possible that higher doses or other
routes of administration (e.g. intravenously) would be more
effective.
The investigation of the possible otoprotective effect of
NAC therapy in this special group of dialysis patients is, in
our opinion, especially important. ESRD patients treated by
hemodialysis are subjected to enhanced oxidative stress due
to increased reactive oxygen species generation (uremic
syndrome, chronic inflammatory state, bioincompatibility of
dialysis membranes and solutions) and decreased antioxidant
ability (vitamin C and E deficiency, reduced activity of
glutathione system).27 Elevated oxidative stress in patients
with ESRD is associated with increased cardiovascular
risk.27–29 Although antioxidants were generally ineffective in
preventing cardiovascular events in general population,30 in
two recent trials in hemodialysis patients, antioxidant therapy
(vitamin E and NAC) reduced cardiovascular risk.28,29 On the
basis of the free radical theory of AG ototoxicity, it is logical
to suggest that NAC would be more beneficial in ESRD
patients than in the general population.
The study has several limitations. First, the initial hearing
examination was performed during acute sepsis. Acute illness
may affect the audiometric examination and accordingly lead
to underestimation of the baseline hearing levels. Second, this
study did not address either laboratory investigation of
vestibular ototoxicity by electronystagmography or evalua-
tion of cochlear function by otoacoustic emissions measure-
ment. These instrumental tests were considered to be too
distressing for seriously ill septic patients. Third, this is a
single-center trial and further studies are needed in a larger
cohort of patients.
In conclusion, our data suggest that NAC may be used as a
simple, effective, and safe drug for prevention of AG
ototoxicity in hemodialysis patients. Further studies are
needed to investigate the possible otoprotective effect of NAC
in other clinical conditions associated with increased
oxidative stress such as diabetes mellitus, chronic inflamma-
tion, and malnutrition.
MATERIALS AND METHODS
Study population
The study included patients with ESRD treated with hemodialysis,
aged 18 years or older, who were candidates for gentamicin
treatment due to dialysis catheter-related bacteremia, in Assaf
Harofeh Medical center, between 1 July 2002 and 1 July 2005. We
defined suspected dialysis catheter-related bacteremia as fever more
than 381C and/or shaking chills in a patient with a dual-lumen
(either cuffed or uncuffed) catheter for whom no other source of
infection was obvious. Clinically suspected bacteremia was con-
sidered to be sufficient for immediate initiation of empirical
antibacterial therapy without waiting for its bacteriological con-
firmation. Patients were excluded if they were treated with AG
within the previous 3 months; had known allergy to AG, mechanical
occlusion of external ear by wax or foreign body; signs of disturbed
integrity of tympanic membrane on otoscopy or tympanometry;
inability to undergo audiometric studies in the first 72 h after the
start of the gentamicin therapy or to cooperate with serial
audiograms; air-bone gaps of greater than 10 dB at any audiometric
frequency for exclusion of a conductive component of hearing loss;
treatment by NAC for other reasons or by any other known
antioxidants, including herbal medications, simultaneous therapy
with other potentially ototoxic drugs such as vancomicin,
furosemide, or more than 100 mg of acetylsalicylic acid per day.
The study was approved by the local Helsinki Committee of Assaf
Harofeh Medical Center (Israel), and all patients signed an informed
consent before their inclusion in the study.
Study design
This is a prospective randomized controlled open label study. After
enrollment, patients were randomly assigned to receive either
gentamicin (Gentamicins; Teva, Petah-Tikva, Israel) with NAC
(Sirans tablets; Temmler Pharma GmbH&Co. KG, Marburg,
Germany) 600 mg twice daily (treatment group) or gentamicin
alone (control group). Two venous blood cultures (one from the
central line and another from the peripheral vein) were obtained
immediately before therapy. The initial empirical therapy for line
sepsis included intravenous infusion of 2 mg/kg of gentamicin over
30 min together with 2 g of cephazolin after dialysis until specific
pathogens were isolated.
Blood gentamicin levels were measured with the use of
fluorescence polarization immunoassay before each consecutive
hemodialysis session. Subsequently, gentamicin dose was adminis-
tered to keep therapeutic trough predialysis level of 2–4 mcg/ml.
Blood gentamicin level measurements and appropriate dosage
changes were supervised by staff physicians on call, not involved
in study process. Duration of treatment was at the discretion of the
patient’s physician according to the patient’s condition, including
blood culture results, clinical course of bacteremia, removal or
preservation of dialysis catheter. Treatment with NAC was continued
until the first follow-up otologic examination, 1 week73 days after
completing gentamicin therapy. Compliance with oral therapy using
NAC was ascertained by tablet’s count in the drug package during
each dialysis session.
Ototoxicity evaluation
Within 72 h after the initiation of gentamicin therapy, all patients
underwent otoscopic examination and baseline tympanometry and
speech audiometry. Patients’ otologic complaints, such as tinnitus
and dizziness, were recorded. Pure-tone audiometry was performed
by a certified audiologist in the audiologic laboratory of Assaf
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Harofeh Medical Center with GSI 16 Audiometer (Grason-Stadler
Inc., Milford, NH 03055-3056, USA) using a standard technique of
pure tone air and bone conduction thresholds measurement at
frequencies of 250, 500, 1 000, 2 000, 3 000, 4 000, 6 000, 8 000, and
12 000 Hz. Only patients with high level of audiometric reliability, as
assessed by an audiologist, were included in the study. The measured
frequencies were gathered in three groups and the pure-tone average
(PTA) was calculated: 250, 500, and 1 000 Hz (PTA-1); 2 000, 3 000,
and 4 000 Hz (PTA-2); and 6 000, 8 000, and 12 000 Hz (PTA-3).
Follow-up otologic examinations were carried out 773 days (‘early’
follow-up) and 4273 days (‘late’ follow-up) after completing
gentamicin therapy. Audiometer was calibrated in accordance with
American National Standards Institute (ANSI) specifications
and was recalibrated every 6 months during the study period.
Hearing impairment was evaluated by using the criteria of the
American Speech-Language-Hearing Association (ASHA 1994).31
Auditory toxicity was defined as an increase in the auditory
threshold by at least 20 dB at any one test frequency or at least 10 dB
at any two adjacent frequencies or loss of response at three
consecutive frequencies between the baseline and follow-up studies
in the worse ear. Neither the audiologist nor the study’s contributor
who analyzed the audiograms was aware of the patient’s group
allocation.
Baseline data collections
Baseline blood pressures were recorded and blood samples were
collected before dialysis session. Adequacy of hemodialysis was
estimated using fractional clearance of urea as a function of its
distribution volume (Kt/V) and was determined by the Kt/V natural
logarithm formula.32 The most recent Kt/V obtained within 1 month
before inclusion to this study was referred as baseline Kt/V.
Statistical analysis
Continuous baseline variables were compared between the treat-
ment groups by an unpaired t-test and by a paired t-test within each
group. Categorical parameters were compared by the Fisher’s exact
test. The effect of NAC treatment on auditory function at baseline, 1
week73 days and 6 weeks73 days after the end of gentamicin
therapy, was compared between the groups by a general linear model
repeated measures analysis of variance (ANOVA). The statistical
software SPSS (version 10.0, SPSS Inc., Chicago, IL, USA) was used
for all analyses. All tests were two-tailed. P-values o0.05 were
considered significant. Data are expressed as mean7s.e.m.
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